WEC
MACK

Winslow Evans & Crocker’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Winslow Evans & Crocker’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,779
Closed -$6.17K – 1160
2018
Q3 		$8K Hold
1,779
– – ﹤0.01% 873
2018
Q2 		$8K Buy
+1,779
New +$11.8K ﹤0.01% 877

Other funds holding MACK

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SC
Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Winslow Evans & Crocker's MACK Position: Q4 2018 in Review

Winslow Evans & Crocker sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2018, closing a stake of 1,779 shares — an estimated $6.17K sold.

Winslow Evans & Crocker first reported a position in MACK in Q2 2018 and held it in 2 quarters. The position peaked at $8K in Q3 2018. 56 funds tracked by Wall St. Rank hold MACK as of Q4 2018.

  • Winslow Evans & Crocker reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Winslow Evans & Crocker sold 1,779 Merrimack Pharmaceuticals, Inc. shares in Q4 2018, an estimated $6.17K.
  • Winslow Evans & Crocker first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2018 and held it in 2 quarters.
  • Winslow Evans & Crocker's Merrimack Pharmaceuticals, Inc. position peaked at $8K in Q3 2018.
  • 56 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2018.

Based on Winslow Evans & Crocker's 13F filing for Q4 2018, filed 23 Jan 2019.